Growth Hormone Replacement Changes Brain Chemistry — First Direct Evidence | Research

The takeaway

One month of GH replacement in deficient adults changed CSF levels of GH, IGF-1, monoamine metabolites, neuropeptides, and opioid peptides.

Placebo-controlled proof
Double-blind trial showing GH replacement directly changes brain opioid peptides, neurotransmitters, and growth factors

What the researchers found

One month of GH replacement increased CSF GH and IGF-1 while altering monoamine metabolites, neuropeptides, and opioid peptide concentrations.

Why it matters

GH-deficient adults report improved mood, energy, and cognition on GH replacement. This study provides the first direct evidence that GH treatment changes brain chemistry, offering a biological explanation for these improvements.

How the study worked

Double-blind, placebo-controlled trial in 20 adults with GH deficiency (10 per group). CSF collected before and after 1 month of treatment (0.25 U/kg/week). Measured GH, IGF-1, IGFBP-3, monoamine metabolites, neuropeptides, and opioid peptides.

What this study cannot tell us

Small study (10 per group). Only 1 month of treatment. CSF sampling is invasive and may have affected some measurements. Long-term brain chemistry effects unknown.

How to read the evidence

Strong — double-blind, placebo-controlled RCT with direct CSF measurement. Gold-standard design despite small size.

When this study was published

Published in 1995 (31 years ago). GH replacement's neurological benefits are now well-recognized.

The bigger picture

GH-deficient patients report improved mood, energy, and cognition on replacement therapy. This study provides a biological explanation: GH treatment actually changes the brain's chemical environment.

Questions still open

Which specific opioid peptide changes correlate with mood improvement?
Do the brain chemistry changes persist long-term?

Common questions

Does growth hormone affect the brain?

Yes — this study directly proved it. GH replacement increased brain GH and IGF-1 levels and changed neurotransmitter and opioid peptide concentrations in the cerebrospinal fluid.

Why do GH-deficient patients feel better on replacement?

This study suggests it's because GH treatment changes brain chemistry — altering monoamine neurotransmitters (affecting mood), neuropeptides (affecting stress response), and opioid peptides (affecting pain and well-being).

Read the original research

Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters.

Neuroendocrinology, 61(1), 57-66

View on PubMed ↗

Citation

Johansson, J O; Larson, G; Andersson, M; Elmgren, A; Hynsjö, L; Lindahl, A; Lundberg, P A; Isaksson, O G; Lindstedt, S; Bengtsson, B A. (1995). Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters.. Neuroendocrinology, 61(1), 57-66.